FEATURED COMPANIES
- AstraZeneca
- BenevolentAI
- Cloud Pharmaceuticals Inc
- GNS Healthcare
- Merck
- NVIDIA Corporation
AI in Pharma Global Market Report 2021: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global ai in pharma market.
This report focuses on ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in pharma market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the ai in pharma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The AI in Pharma market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider ai in pharma market, and compares it with other markets.
Scope
Markets Covered:
1) Technology: Context-Aware Processing; Natural Language Processing; Querying Method; Deep Learning
2) By Drug Type: Small Molecule; Large Molecules
3) By Application: Diagnosis; Clinical Trial Research; Drug Discovery; Research and Development; Epidemic Prediction
Companies Mentioned: Novartis; IBM Watson; Microsoft Corporation; Merck; GNS Healthcare
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This report focuses on ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in pharma market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the ai in pharma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The AI in Pharma market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider ai in pharma market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The ai in pharma market section of the report gives context. It compares the ai in pharma market with other segments of the ai in pharma market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, ai in pharma indicators comparison.
Scope
Markets Covered:
1) Technology: Context-Aware Processing; Natural Language Processing; Querying Method; Deep Learning
2) By Drug Type: Small Molecule; Large Molecules
3) By Application: Diagnosis; Clinical Trial Research; Drug Discovery; Research and Development; Epidemic Prediction
Companies Mentioned: Novartis; IBM Watson; Microsoft Corporation; Merck; GNS Healthcare
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global AI in Pharma Market
What is the estimated value of the Global AI in Pharma Market?
What is the growth rate of the Global AI in Pharma Market?
What is the forecasted size of the Global AI in Pharma Market?
Who are the key companies in the Global AI in Pharma Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca
- BenevolentAI
- Cloud Pharmaceuticals Inc
- GNS Healthcare
- Merck
- NVIDIA Corporation
1. Executive Summary2. AI in Pharma Market Characteristics3. AI in Pharma Market Trends and Strategies4. Impact of COVID-19 on AI in Pharma28. Key Mergers and Acquisitions in the AI in Pharma Market29. AI in Pharma Market Future Outlook and Potential Analysis
5. AI in Pharma Market Size and Growth
6. AI in Pharma Market Segmentation
7. AI in Pharma Market Regional and Country Analysis
8. Asia-Pacific AI in Pharma Market
9. China AI in Pharma Market
10. India AI in Pharma Market
11. Japan AI in Pharma Market
12. Australia AI in Pharma Market
13. Indonesia AI in Pharma Market
14. South Korea AI in Pharma Market
15. Western Europe AI in Pharma Market
16. UK AI in Pharma Market
17. Germany AI in Pharma Market
18. France AI in Pharma Market
19. Eastern Europe AI in Pharma Market
20. Russia AI in Pharma Market
21. North America AI in Pharma Market
22. USA AI in Pharma Market
23. South America AI in Pharma Market
24. Brazil AI in Pharma Market
25. Middle East AI in Pharma Market
26. Africa AI in Pharma Market
27. AI in Pharma Market Competitive Landscape and Company Profiles
30. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca
- BenevolentAI
- Cloud Pharmaceuticals Inc
- GNS Healthcare
- Merck
- NVIDIA Corporation
Major players in the artificial intelligence (AI) in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Inc., Exscientia, and Cyclica.
The global AI in pharma market is expected to grow from $0.91 billion in 2020 to $1.27 billion in 2021 at a compound annual growth rate (CAGR) of 39%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.94 billion in 2025 at a CAGR of 47%.
The artificial intelligence (AI) in pharma market consists of sales of AI in the pharma and related services that use an automated algorithm to perform tasks that traditionally rely on human intelligence. It can be useful in handling data and presenting results that encourage better decision-making and save human efforts, cost, and time. The market consists of revenue generated by artificial intelligence (AI) companies, which are applying in the pharmaceutical industry. Only goods and services traded between entities or sold to end consumers are included.
The artificial intelligence (AI) in pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, deep learning; by drug type into small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction.
North America was the largest region in the AI in pharma market in 2020. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market.
In November 2018, Cyclica, a Canadian biotechnology company that leverages AI and computational biophysics to decentralize drug discovery collaborated with Bayer on drug discovery programs. These companies will increase drug discovery applications by increasing intelligence into the polypharmacological outlines of small molecules while further developing Cyclica’s integrated system of licensing technologies. Bayer, a German multinational pharmaceutical company, includes human and veterinary pharmaceuticals, agricultural chemicals, seeds, and biotechnology products.
The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market.
Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation. For instance, in September 2019, Novartis and Microsoft announced a multiyear alliance that will leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized. Further, Novartis also established an AI Innovation Lab to empower associates to use AI across their business. Therefore, companies operating in the market are continuously focusing on introducing new technologies to survive in the AI in the pharma market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The global AI in pharma market is expected to grow from $0.91 billion in 2020 to $1.27 billion in 2021 at a compound annual growth rate (CAGR) of 39%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.94 billion in 2025 at a CAGR of 47%.
The artificial intelligence (AI) in pharma market consists of sales of AI in the pharma and related services that use an automated algorithm to perform tasks that traditionally rely on human intelligence. It can be useful in handling data and presenting results that encourage better decision-making and save human efforts, cost, and time. The market consists of revenue generated by artificial intelligence (AI) companies, which are applying in the pharmaceutical industry. Only goods and services traded between entities or sold to end consumers are included.
The artificial intelligence (AI) in pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, deep learning; by drug type into small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction.
North America was the largest region in the AI in pharma market in 2020. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market.
In November 2018, Cyclica, a Canadian biotechnology company that leverages AI and computational biophysics to decentralize drug discovery collaborated with Bayer on drug discovery programs. These companies will increase drug discovery applications by increasing intelligence into the polypharmacological outlines of small molecules while further developing Cyclica’s integrated system of licensing technologies. Bayer, a German multinational pharmaceutical company, includes human and veterinary pharmaceuticals, agricultural chemicals, seeds, and biotechnology products.
The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market.
Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation. For instance, in September 2019, Novartis and Microsoft announced a multiyear alliance that will leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized. Further, Novartis also established an AI Innovation Lab to empower associates to use AI across their business. Therefore, companies operating in the market are continuously focusing on introducing new technologies to survive in the AI in the pharma market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Novartis
- IBM Watson
- Microsoft Corporation
- Merck
- GNS Healthcare
- AstraZeneca
- Atomwise Inc.
- Exscientia
- Cyclica
- NVIDIA Corporation
- XtalPi Inc.
- BenevolentAI
- Cloud Pharmaceuticals Inc
- BERG LLC
- Bayer
- Pfizer
- Recursion Pharmaceuticals Inc.
- Bristol-Myers Squibb
Note: Product cover images may vary from those shown
LOADING...